
Medicus Pharma advances SkinJect and Pfizer partnership in precision oncology with new clinical and funding updates
Medicus Pharma has confirmed the 200-microgram dose of its SkinJect patch for further studies targeting Gorlin syndrome, with FDA approval for a pivotal trial underway. The company is also exploring an out-licence for nodular basal cell carcinoma and...





